BioAegis COO and Co-founder, Valerie Ceva, was invited to present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City. The presentation, “Conquering Disease Driven by Excess Inflammation” will highlight BioAegis’ novel, host-directed immune regulator protein. The presentation will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (ARDS), and its phase 2 global clinical study.